AI-generated summary
The authors report a randomized study of 160 melasma patients comparing laser alone with laser combined with topical tranexamic acid. The combined group showed smaller melasma area and depth after treatment, persisting at 6 and 12 months, with fewer side effects and higher patient satisfaction. The abstract describes these as the authors' findings from a single hospital.
- Participants
- 160
- Who or what was studied
- Melasma patients treated in one dermatology department from May 2021 to October 2022, randomly assigned to laser only (n = 80) or laser plus topical tranexamic acid (n = 80)
- Limits stated in the abstract
- The abstract does not describe the laser type, dosing, blinding or follow-up dropout, and the study was conducted at a single hospital.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.